APTO Common Shares Removed from Nasdaq Listing via Form 25

Rhea-AI Filing Summary

Nasdaq Stock Market LLC has submitted Form 25 to the SEC to remove Aptose Biosciences Inc. (APTO) common shares from listing and registration under Section 12(b) of the Exchange Act. The filing, dated 21 July 2025, states that both the exchange and the issuer have complied with the relevant provisions of 17 CFR 240.12d2-2 for striking or voluntarily withdrawing the securities. The notification is signed on Nasdaq’s behalf by Hearings Advisor Aravind Menon. No financial metrics, reasons for delisting, or additional corporate actions are disclosed in the document.

Positive

• None.

Negative

• Nasdaq filed Form 25 to strike APTO common shares from listing and registration, ending the security’s status on a major exchange.

Insights

Securities Analyst

TL;DR: Nasdaq’s Form 25 ends APTO’s Nasdaq listing; absence of financial data leaves impact context limited.

The filing formally terminates the quotation and registration of Aptose Biosciences’ common shares on Nasdaq. Without supplementary information, investors only know the administrative fact of delisting, which generally reduces exchange visibility. The document cites compliance with Rules 12d2-2(b) and (c) but provides no explanation for the action. Because listing status often influences liquidity and institutional eligibility, the event is typically viewed as adverse, though its full significance cannot be gauged without additional disclosures.

UNITED STATES

OMB APPROVAL

OMB Number:			3235-0080
Expires:	March 31, 2018
Estimated average burden
hours per response:			1.7

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 25

NOTIFICATION OF REMOVAL FROM LISTING AND/OR REGISTRATION
UNDER SECTION 12(b) OF THE SECURITIES EXCHANGE ACT OF 1934.

Commission File Number

001-32001

Issuer:	Aptose Biosciences Inc.
Exchange:	Nasdaq Stock Market LLC

(Exact name of Issuer as specified in its charter, and name of Exchange where security is listed and/or registered)

Address:	5955 Airport Road, Suite 228
	Mississauga	ONTARIO, CANADA	L4V 1R9
Telephone number:					4,152,184,035

(Address, including zip code, and telephone number, including area code, of Issuer's principal executive offices)

Common Shares

(Description of class of securities)

Please place an X in the box to designate the rule provision relied upon to strike the class of securities from listing and registration:

17 CFR 240.12d2-2(a)(1)

17 CFR 240.12d2-2(a)(2)

17 CFR 240.12d2-2(a)(3)

17 CFR 240.12d2-2(a)(4)

Pursuant to 17 CFR 240.12d2-2(b), the Exchange has complied with its rules to strike the class of securities from listing and/or withdraw registration on the Exchange. ¹

Pursuant to 17 CFR 240.12d2-2(c), the Issuer has complied with its rules of the Exchange and the requirements of 17 CFR 240.12d-2(c) governing the voluntary withdrawal of the class of securities from listing and registration on the Exchange.

Pursuant to the requirements fo the Securities Exchange Act of 1934, Nasdaq Stock Market LLC certifies that it has reasonable grounds to believe that it meets all of the requirements for filing the Form 25 and has caused this notification to be signed on its behalf by the undersigned duly authorized person.

2025-07-21	By	Aravind Menon		Hearings Advisor
Date		Name		Title

¹ Form 25 and attached Notice will be considered compliance with the provisions of 17 CFR 240.19d-1 as applicable. See General Instructions.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

What did Nasdaq file regarding Aptose Biosciences (APTO)?

Nasdaq filed Form 25 to remove APTO common shares from listing and registration under Section 12(b).

When was the Form 25 for APTO submitted?

The notification is dated 21 July 2025.

Which class of securities is affected by the Form 25?

The filing applies to Common Shares of Aptose Biosciences Inc.

Which regulatory rules are cited in the delisting notice?

Nasdaq references 17 CFR 240.12d2-2(b) and 17 CFR 240.12d2-2(c) for compliance.

Who signed the Form 25 on behalf of Nasdaq?

The document is signed by Aravind Menon, Hearings Advisor.